Based on the metaplastic breast-carcinoma cell line with EGFR amplification from a patient using the CR method, Chung et al. discovered that the combination of EGFR inhibitor and paclitaxel was a promising strategy for metaplastic breast-carcinoma with EGFR amplification [113]. Here, EGFR is linked to breast carcinoma.